Filtered By:
Condition: Pain
Vaccination: Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1735 results found since Jan 2013.
Continued challenges in pediatric anesthesia during COVID-19 in 2022: An international survey from the pediatric anesthesia COVID-19 collaborative
CONCLUSION: Our study found that COVID-19 has continued to impact pediatric anesthesiology. There are major discrepancies between what anesthesiologists believe are important for job satisfaction and faculty retention compared to implemented initiatives. Data from this survey provide insight for institutions and departments for addressing these challenges.PMID:37732382 | DOI:10.1111/pan.14762
Source: Pain Physician - September 21, 2023 Category: Anesthesiology Authors: John Zhong Victoria Bradford Allison M Fernandez Andrew Infosino Codruta N Soneru Steven J Staffa Vidya T Raman Joseph Cravero David Zurakowski Petra M Meier Pediatric Anesthesia COVID-19 Collaborative Source Type: research
Omega-3 polyunsaturated fatty acids and the psychiatric post-acute sequelae of COVID-19: A one-year retrospective cohort analysis of 33,908 patients
CONCLUSION: Omega-3 PUFAs may require re-evaluation as a preventive strategy against adverse mental health outcomes post-COVID-19 in placebo-controlled clinical trials.PMID:37716377 | DOI:10.1016/j.bbi.2023.09.008
Source: Brain, Behavior, and Immunity - September 16, 2023 Category: Neurology Authors: Ting-Hui Liu Chung-Han Ho Daniel Tzu-Li Chen Jheng-Yan Wu Po-Yu Huang Chih-Cheng Lai Kuang-Yang Hsieh Kuan-Pin Su Source Type: research
Self-assembling Gn head ferritin nanoparticle vaccine provides full protection from lethal challenge of < em > Dabie bandavirus < /em > in aged ferrets
This study demonstrates that DBV GnH-FT nanoparticles provide an efficient vaccine efficacy in mouse and aged ferret models and should be an outstanding vaccine candidate targeted for the aged population against fatal DBV infection. IMPORTANCE Dabie bandavirus (DBV) is an emerging tick-borne virus that causes severe fever with thrombocytopenia syndrome (SFTS) in infected patients. Human SFTS symptoms progress from fever, fatigue, and muscle pain to the depletion of white blood cells and platelets with fatality rates up to 30%. The recent spread of its vector tick to over 20 states in the United States increases the potenti...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Dokyun Kim Eunha Kim Semi Kim Youseung Chung Chih-Jen Lai Inho Cha Sung-Dong Cho Yunseo Choi Xinghong Dai Stephanie Kim Seokmin Kang Mi-Jeong Kwak Ziyi Liu Younho Choi Su-Hyung Park Young Ki Choi Jae U Jung Source Type: research
Association of Guillain-Barr é syndrome following COVID-19 vaccination
Conclusion: This review highlights the diverse and clinically relevant associations between COVID-19 vaccination and GBS. The findings underscore the importance of conducting further studies to explore the causative links in this correlation and gain a better understanding of the relationship.PMID:37681361 | DOI:10.1177/03946320231199349
Source: International Journal of Immunopathology and Pharmacology - September 8, 2023 Category: Allergy & Immunology Authors: Selia Chowdhury Samia Chowdhury Source Type: research
Telogen effluvium and COVID-19: a cross-sectional study
CONCLUSIONS: In our study, the incidence of TE was highly related to COVID-19 infections among both sexes. However, the incidence was greater among the female population. The awareness level toward post-COVID-19 TE was poor among most of the participants in our study.PMID:37667959 | DOI:10.26355/eurrev_202308_33437
Source: Pharmacological Reviews - September 5, 2023 Category: Drugs & Pharmacology Authors: A Aldahish R Vasudevan H Salem A Alqahtani S AlQasim A Alqhatani M Al Shahrani L Al Mohsen M Hajla D Calina J Sharifi-Rad Source Type: research
Immunogenicity and safety of Havisure < sup > TM < /sup > vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study
CONCLUSION: The study results indicate that the Havisure™ vaccine is immunogenic and safe when administered to healthy subjects of 12 months to 49 years of age, and is non-inferior to Havrix® Vaccine.PMID:37661535 | DOI:10.1016/j.vaccine.2023.08.084
Source: Vaccine - September 4, 2023 Category: Allergy & Immunology Authors: Sai Krishna Susarla Madhu Gupta Kheya Ghosh Uttam Sonali Palkar Ashish Ramachandra Dhongade K Siva Ram Prasad Vasudev Rajapantula M D Ravi N Pradeep M Satish B C Rajashakar G Sandhya L Rajendra Devi Prasad Sahoo Anand Kumar Kanakasapapathy Source Type: research
Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial
This study provides insights into the design of future CMV vaccine efficacy trials, particularly for the identification of CMV infection using molecular assays.FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA (MSD).PMID:37660711 | DOI:10.1016/S1473-3099(23)00343-2
Source: Herpes - September 3, 2023 Category: Infectious Diseases Authors: Rituparna Das Daniel Bl ázquez-Gamero David I Bernstein Soren Gantt Oliver Bautista Karen Beck Anthony Conlon Daniel I S Rosenbloom Dai Wang Michael Ritter Beth Arnold Paula Annunziato Kevin L Russell V160-002 study group Source Type: research
Examining online information-seeking behaviours and antenatal anxiety of expectant fathers
This study was designed to examine online information-seeking behaviours of expectant fathers regarding pregnancy and birth and their antenatal anxiety. The present study was conducted using 120 expectant fathers who accompanied their wives to the maternity outpatient clinic in western Turkey, İzmir Province. The fathers' anxiety levels were assessed using a trait anxiety subscale of the State-Trait Anxiety Inventory (STAI), which is a validated test for scoring trait anxiety (basal anxiety, STAI-T). The results showed that 92.5% of the expectant fathers searched for information online during pregnancy. They most frequent...
Source: Midwifery - September 2, 2023 Category: Midwifery Authors: Duygu G üleç Şatır Source Type: research
Immunogenicity and safety of Mebella ™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study
CONCLUSION: It was concluded from the study results that the test vaccine, Mebella™, was immunogenic and well tolerated and was non-inferior to the comparator vaccine, MR-VAC®, when administered to healthy subjects of 9 months to 49 years of age. Clinical Trial Registry of India Identifier: CTRI/2020/07/026930.PMID:37659893 | DOI:10.1016/j.vaccine.2023.08.065
Source: Vaccine - September 2, 2023 Category: Allergy & Immunology Authors: Sai Krishna Susarla Rahul Jahagirdar Kheya Ghosh Uttam S Srikanth Bhatt S Prashanth Vasudev Rajapantula M Satish B C Rajashakar G Sandhya L Rajendra Devi Prasad Sahoo Anand Kumar Kanakasapapathy Source Type: research
